A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2013
At a glance
- Drugs TAK 783 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 May 2009 Planned number of patients changed from 230 to 224 as reported by ClinicalTrials.gov.
- 01 May 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.